Egis Inaugurates HUF 30 Bn Active Ingredient Plant

Egis Pharmaceuticals Ltd. has unveiled one of the most significant developments in its 112-year history in Budapest. The company will manufacture the active ingredient for a globally leading product at its new HUF 30 billion plant, which was financed from its own resources, the company told MTI on Thursday.

According to the announcement, what makes this brownfield investment special is that the technology is almost identical to that used at the French parent company's plant in Normandy, and the start-up of the plant will double the production of the active ingredient needed for the Servier Group's drug for the treatment of venous diseases.

The plant is technologically almost identical to the French parent company's Normandy plant, and once operational, it will double the production capacity of the active ingredient required for Servier Group's drug for the treatment of venous diseases.

Egis CEO Csaba Poroszlai said the new plant provides capacities that ensure the foundations for long-term development, competitiveness and contribute to security of supply.

Egis had HUF 270 billon revenue in its business year that ended in September 2024, public records show.